15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Castle Biosciences Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $40.00 to $52.00, so the covering firms are broadly aligned. The average target of $44.33 sits 35% above the current $32.76. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.36 next quarter toward $-0.99 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Castle Biosciences Inc.
As of Sep, 6 of 6 firms rate CSTL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CSTL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.36
Range $-0.45 – $-0.25 · 9 analysts · +356% YoY
Next period, 9 analysts expect Castle Biosciences Inc to earn $-0.36 a share (range $-0.45 – $-0.25), versus $-0.08 a year earlier. Full-year consensus is $-1.27, growing to $-0.99 the year after.
REVENUE · NEXT QUARTER
$93.8M
Range $92.9M – $94.8M · 9 analysts · +8% YoY
Revenue is expected to reach $93.8M (range $92.9M – $94.8M), +7.9% year-over-year. Full-year consensus is $372.9M, rising to $409.4M next year.
Top analysts covering Castle Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CSTL.
#1
SJ
Sung Ji Nam
Scotiabank · Rank #140
Buy
$40.00+22.1% to target
Overall win rate
46%
+ Follow
#2
TF
Thomas Flaten
Lake Street · Rank #238
Buy
$52.00+58.7% to target
Overall win rate
40%
+ Follow
#3
KM
Kyle Mikson
Canaccord Genuity · Rank #263
Buy
$40.00+22.1% to target
Overall win rate
34%
+ Follow
#4
Paul Knight
Keybanc · Rank #341
Buy
$35.00+6.8% to target
Overall win rate
35%
+ Follow
#5
Mark Massaro
BTIG
Buy
$44.00+34.3% to target
Coverage
—
+ Follow
CSTL stock forecast FAQ
What is CSTL's average 12-month price target?+
The 6 analysts with a live target average $44.33 for Castle Biosciences Inc over the next 12 months, ranging from a $52.00 high to a $40.00 low.
Is CSTL stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CSTL?+
The Street-high target is $52.00 (Lake Street), and the Street-low is $40.00 (Roth Capital). The average of all 6 active targets is $44.33.
How many Wall Street analysts cover CSTL?+
6 analysts have an active rating on Castle Biosciences Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering CSTL?+
Among analysts who currently cover CSTL, Sung Ji Nam of Scotiabank has the strongest overall Quantellect track record (Rank #140). Their current call is Buy with a $40.00 target.
What is Castle Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.36 per share (range $-0.45 – $-0.25) across 9 analysts. Full-year EPS is projected at $-1.27, rising to $-0.99 the following year.
How much revenue is Castle Biosciences Inc expected to report next quarter?+
Consensus revenue is $93.8M (range $92.9M – $94.8M). Full-year revenue is projected at $372.9M, growing to $409.4M next year.
Have analysts been upgrading or downgrading CSTL lately?+
As of Sep, 6 of 6 firms rate CSTL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CSTL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
